Contents
In this guide
In this guideOn this page
Skip the menu of subheadings on this page.Contents
|
Annex A |
13 |
|
Discussion paper on novel formulations of supplement compounds designed to increase oral bioavailability |
13 |
|
Novel formulations of supplement compounds |
14 |
|
Lipid based delivery systems |
14 |
|
Background and overview |
14 |
|
Emulsions |
18 |
|
Micelles |
20 |
|
Liposomes |
20 |
|
Lipid nanoparticles |
22 |
|
Mechanisms of enhanced bioavailability in lipid based delivery systems |
27 |
|
Other systems to increase bioavailability |
35 |
|
Uncertainties surrounding novel supplement formulations |
37 |
|
Market data and projected trends |
39 |
|
Case studies of supplement formulations with increased bioavailability |
42 |
|
Case study 1: Liposomal vitamin C |
42 |
|
Case study 2: Curcuminoids |
47 |
|
Review by Jamwal, 2018 |
47 |
|
Other studies |
50 |
|
Case study 3: Cannabidiol |
59 |
|
Background |
|
|
Studies investigating the oral pharmacokinetics of CBD formulations |
60 |
|
Toxicology studies with novel supplement formulations |
65 |
|
Curcumin |
67 |
|
Summary and discussion |
68 |
|
Questions for the Committee |
70 |
|
Abbreviations and glossary |
72 |
|
Abbreviations |
72 |
|
Glossary |
74 |
|
References |
77 |
|
Appendix A: Literature search for specific toxicology studies with novel supplement formulations |
94 |